Apricus Biosciences, Inc (APRI) Receives Buy Rating from HC Wainwright
Separately, Zacks Investment Research raised shares of Apricus Biosciences from a sell rating to a hold rating in a report on Wednesday, July 12th.
Shares of Apricus Biosciences (NASDAQ APRI) traded down $0.12 during mid-day trading on Friday, reaching $1.57. 376,912 shares of the company’s stock traded hands, compared to its average volume of 207,321. Apricus Biosciences has a 52 week low of $0.86 and a 52 week high of $4.07.
Apricus Biosciences (NASDAQ:APRI) last posted its quarterly earnings results on Thursday, November 2nd. The company reported ($0.30) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.15). During the same quarter last year, the business earned ($0.19) EPS. sell-side analysts predict that Apricus Biosciences will post -0.81 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This report was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/11/05/apricus-biosciences-inc-apri-receives-buy-rating-from-hc-wainwright.html.
About Apricus Biosciences
Apricus Biosciences, Inc is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT.
Receive News & Stock Ratings for Apricus Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences Inc and related stocks with our FREE daily email newsletter.